Forschung & Innovation
Publikationen
Assessment of Treatment Response to Lenvatinib in Thyroid Cancer Monitored by F-18 FDG PET/CT Using PERCIST 1.0, Modified PERCIST and EORTC Criteria-Which One Is Most Suitable?
PMU Autor*innen
Gundula Rendl, Gregor Schweighofer-Zwink, Wolfgang Hitzl, Christian Pirich
Alle Autor*innen
Gundula Rendl, Gregor Schweighofer-Zwink, Stefan Sorko, Hans-Jürgen Gallowitsch, Wolfgang Hitzl, Diana Reisinger, Christian Pirich
Fachzeitschrift
Cancers
Kurzfassung
Keywords
MANAGEMENT, DOUBLE-BLIND, PARAMETERS, SOLID TUMORS, METASTASES, CARCINOMA, TYROSINE KINASE INHIBITORS, EMISSION-TOMOGRAPHY, PROGNOSTIC VALUE, SORAFENIB